Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Boceprevir

FDA-approved product (capsule, oral), marketed as Victrelis.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Boceprevir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Boceprevir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Boceprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)

    NCT01641666 · start 2014-05

    Registered record
    Registry ID
    NCT01641666
    Conditions
    Chronic Hepatitis C
    Interventions
    Boceprevir; Peginterferon Alfa-2b 1.5 mcg/kg/week; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2014-05
    Completion
    2016-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionBoceprevir; Peginterferon Alfa-2b 1.5 mcg/kg/week; Ribavirin
    PhasePhase 3
    Registry statusWithdrawn

  • A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

    NCT01770223 · start 2014-01

    Registered record
    Registry ID
    NCT01770223
    Conditions
    Hepatitis C
    Interventions
    boceprevir; PegIFN-2b; RBV
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2014-01
    Completion
    2015-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    Interventionboceprevir; PegIFN-2b; RBV
    PhasePhase 4
    Registry statusWithdrawn

  • Boceprevir Treatment in Liver Pre-transplant HCV Patients

    NCT02160080 · start 2014-01

    Registered record
    Registry ID
    NCT02160080
    Conditions
    Late Complication From Liver Transplant
    Interventions
    Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2017-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLate Complication From Liver Transplant
    InterventionBoceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
    PhasePhase 3
    Registry statusUnknown

  • Register of Telaprevir and Boceprevir in Routine Clinical Practice

    NCT02004379 · start 2013-11

    Registered record
    Registry ID
    NCT02004379
    Conditions
    Hepatitis C
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-11
    Completion
    2015-06
    Enrolment
    1,553

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy

    NCT02060058 · start 2013-11

    Registered record
    Registry ID
    NCT02060058
    Conditions
    Hepatitis C, Chronic
    Interventions
    Stop trial intervention for boceprevir, PEG-IFN and RBV
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-11
    Completion
    2016-09
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionStop trial intervention for boceprevir, PEG-IFN and RBV
    PhasePhase 3
    Registry statusCompleted

  • A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV

    NCT01949168 · start 2013-09

    Registered record
    Registry ID
    NCT01949168
    Conditions
    Chronic Hepatitis C
    Interventions
    Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets); Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection; Rebetol® (ribavirin), 1000/1200mg by mouth daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2013-09
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionVictrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets); Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection; Rebetol® (ribavirin), 1000/1200mg by mouth daily
    PhasePhase 2
    Registry statusUnknown

  • Dutch Acute HCV in HIV Study (DAHHS)

    NCT01912495 · start 2013-08

    Registered record
    Registry ID
    NCT01912495
    Conditions
    Hepatitis C; Human Immunodeficiency Virus
    Interventions
    Boceprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-08
    Completion
    2016-01
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Human Immunodeficiency Virus
    InterventionBoceprevir
    PhasePhase 2
    Registry statusCompleted

  • Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C

    NCT01925183 · start 2013-08

    Registered record
    Registry ID
    NCT01925183
    Conditions
    Hepatitis C, Chronic; HIV
    Interventions
    Pegylated interferon alpha-2a; Ribavirin; Boceprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-08
    Completion
    2015-06
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic; HIV
    InterventionPegylated interferon alpha-2a; Ribavirin; Boceprevir
    PhasePhase 4
    Registry statusCompleted

  • Boceprevir in End Stage Renal Disease (ESRD)

    NCT02112630 · start 2013-05

    Registered record
    Registry ID
    NCT02112630
    Conditions
    Hepatitis C Infection; End Stage Renal Disease
    Interventions
    P-IFN alfa 2a; P-IFN alfa 2b; Ribavirin; Boceprevir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2013-05
    Completion
    2015-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Infection; End Stage Renal Disease
    InterventionP-IFN alfa 2a; P-IFN alfa 2b; Ribavirin; Boceprevir
    PhaseNot applicable
    Registry statusWithdrawn

  • HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin

    NCT01718301 · start 2013-03-10

    Registered record
    Registry ID
    NCT01718301
    Conditions
    Hepatitis C; HIV Infections; COINFECTION
    Interventions
    boceprevir; Ribavirin; Peginterferon alfa-2a; Peginterferon alfa-2b
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2013-03-10
    Completion
    2015-06-30
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; HIV Infections; COINFECTION
    Interventionboceprevir; Ribavirin; Peginterferon alfa-2a; Peginterferon alfa-2b
    PhasePhase 3
    Registry statusTerminated

  • Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)

    NCT01590225 · start 2013-01-28

    Registered record
    Registry ID
    NCT01590225
    Conditions
    Chronic Hepatitis C
    Interventions
    Boceprevir; Peginterferon alpha-2b; Ribavirin; Boceprevir; Peginterferon alfa-2b; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2013-01-28
    Completion
    2021-08-18
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionBoceprevir; Peginterferon alpha-2b; Ribavirin; Boceprevir +2 more
    PhasePhase 3
    Registry statusWithdrawn

  • A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

    NCT01731301 · start 2013-01

    Registered record
    Registry ID
    NCT01731301
    Conditions
    Chronic Hepatitis C; End Stage Renal Disease
    Interventions
    Ribavirin; Peginterferon; Boceprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-01
    Completion
    2015-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C; End Stage Renal Disease
    InterventionRibavirin; Peginterferon; Boceprevir
    PhasePhase 4
    Registry statusUnknown

  • The Boceprevir and Sildenafil Pharmacokinetics Study

    NCT01499498 · start 2012-12

    Registered record
    Registry ID
    NCT01499498
    Conditions
    Hepatitis C
    Interventions
    Sildenafil and Boceprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-12
    Completion
    2014-05
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionSildenafil and Boceprevir
    PhasePhase 1
    Registry statusCompleted

  • Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects

    NCT01657552 · start 2012-08-01

    Registered record
    Registry ID
    NCT01657552
    Conditions
    Thrombocytopaenia
    Interventions
    Eltrombopag; Boceprevir; Telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-08-01
    Completion
    2012-10-26
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocytopaenia
    InterventionEltrombopag; Boceprevir; Telaprevir
    PhasePhase 1
    Registry statusCompleted

  • A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

    NCT01591460 · start 2012-08

    Registered record
    Registry ID
    NCT01591460
    Conditions
    Hepatitis C, Chronic
    Interventions
    boceprevir; peginterferon alfa-2a [Pegasys]; peginterferon alfa-2a [Pegasys]; ribavirin (Copegus]; ribavirin (Copegus]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-08
    Completion
    2014-06
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    Interventionboceprevir; peginterferon alfa-2a [Pegasys]; peginterferon alfa-2a [Pegasys]; ribavirin (Copegus] +1 more
    PhasePhase 4
    Registry statusCompleted